ライフサイエンスコーパス: TIPS

1 TIPS after LT can be clinically effective in patients wi

2 TIPS provides a possible first step toward HTLV-1 leukem

3 TIPS succeeds in lowering the hepatic sinusoidal pressur

4 TIPS volume of </= 20 TIPS/year, variceal bleeding, and

5 TIPS was associated with higher rates of early hepatic e

6 TIPS was technically successful in all 91 patients (12 i

7 TIPS was used more frequently in the tamponade group (4

8 TIPS were placed in all 5529 patients (mean age, 57 year

9 TIPS-acetylene-substituted benzene-1,2-diol and naphthal

10 TIPS-ethynyl groups are not bulky enough to allow stabil

11 orms the geminate radical ion pair state (1)(TIPS-Pn(+*)-PDI(-*)) that undergoes radical pair intersy

12 ition between ultrafast singlet fission ((1*)TIPS-Pn + TIPS-Pn --> 2 (3*)TIPS-Pn) and charge transfer

13 2 (3*)TIPS-Pn) and charge transfer from (1*)TIPS-Pn to PDIs 1-3.

14 ality is lower in hospitals performing >/=20 TIPS per year.

15 TIPS volume of </= 20 TIPS/year, variceal bleeding, and nosocomial infections

16 adical pair intersystem crossing to form (3)(TIPS-Pn(+*)-PDI(-*)), which then undergoes charge recomb

17 let fission ((1*)TIPS-Pn + TIPS-Pn --> 2 (3*)TIPS-Pn) and charge transfer from (1*)TIPS-Pn to PDIs 1-

18 recombination to yield either (3*)PDI or (3*)TIPS-Pn.

19 show that multiple pathways produce the (3*)TIPS-Pn state, so that OPV design strategies based on th

20 sfer from (3*)PDI to TIPS-Pn also yields (3*)TIPS-Pn.

21 on (22 patients angioplasty/thrombolysis, 62 TIPS, and 20 OLT) and 36 (22.9%) died.

22 zinc chlorins, the series of substituents (7-TIPS-ethynyl, 7-acetyl, 7-formyl) progressively causes (

23 unique signature of a hidden interface in a TIPS-pentacene thin film, exposing its exciton dynamics

24 The introduction of a TIPS-ethynyl, acetyl, or formyl group at the 7-position

25 After TIPS, central venous pressure (median, 11 vs 15 cm H(2)O

26 nd PV (0.88 L/min; 95% CI: 0.06, 1.70) after TIPS placement (all P < .05), with no significant differ

27 were performed 1 to 7 days before and after TIPS at months 1, 3, 6, 9, and 12 or until liver transpl

28 t to PV flow, were compared before and after TIPS placement by using analysis of variance.

29 oring of hepatic blood flow before and after TIPS placement.

30 sociated with a decrease in creatinine after TIPS (R = 0.816, P < .001).

31 ICG-PDR significantly deteriorated after TIPS (P = .006).

32 t the concept that PPG value <12 mm Hg after TIPS placement is associated with reduced risk of bleedi

33 ally stable patients at least 24 hours after TIPS to be the best maintained values.

34 V and incomplete patent PV immediately after TIPS was 57.05 +/- 0.75 vs. 39.12 +/- 2.64 months, respe

35 vival and vascular patency immediately after TIPS.

36 edation (early PPG); and again 1 month after TIPS placement (late PPG).

37 term (>3 months) need for paracentesis after TIPS placement were evaluated and calculated by using th

38 lues measured at different time points after TIPS placement, we found measurements of PPG in awake, h

39 nts collected at different time points after TIPS, aiming to identify a time point after which PPG va

40 Median change in the PSG after TIPS was 11 mm Hg (1-27 mm Hg).

41 vered stent-graft was superior to that after TIPS with the nitinol stent-graft.

42 tory ascites before and 2 and 12 weeks after TIPS placement by using a time-resolved three-dimensiona

43 ICT lures significantly worsened after TIPS (n = 10; 5 vs 9, respectively; P = .02) and improve

44 ollowing EPCS compared with 1.99 years after TIPS.

45 entafluorophenyl 4-maleimidobenzoate (1) and TIPS-protected N-propargyl maleimide (2).

46 to 7 times greater in the EEST ($168100) and TIPS ($264800) groups than in the EPCS ($39000) group (P

47 y greater following EPCS than after EEST and TIPS (P<.001).

48 10-diphenylanthracene, perylene, rubrene and TIPS-pentacene, are reported.

49 ation-electrophilic fluorination of TMS- and TIPS-protected 1,3-benzothiazol-2-yl (BT) propargyl sulf

50 more common in hospitals with higher annual TIPS volume (20.3% for very low to 30.8% for very high;

51 s categorized into quintiles based on annual TIPS volume (very low, 1-4/year; low, 5-9/year; medium,

52 Mortality decreased with rising annual TIPS volume (13% for very low to 6% for very high volume

53 Appropriate TIPS procedures were performed based on our more specifi

54 We conclude that appropriate TIPS procedures and lower grade of PVT are essential for

55 ile the use of bulkier silyl groups, such as TIPS, resulted unproductive.

56 Moreover, BCS-TIPS prognostic index (PI) score (based on international

57 cting intervention-free survival and the BCS-TIPS PI score for predicting survival.

58 Before TIPS, MHE was detected by PHES and CFF in 33% and 39% of

59 (triisopropylsilyl)ethynylmagnesium bromide (TIPS-CC-MgBr) leads to a distribution of mono-, bis-, an

60 ere extensively controlled by a remote bulky TIPS group.

61 d by EEST in only 20% of the patients and by TIPS in only 22%.

62 n-2 is recruited to growing microtubules by +TIPS and that the motor protein steers growing microtubu

63 e use of bare stents and most patients chose TIPS 2-3 years after traditional treatment, thus making

64 Collectively, TIPS is an effective and safe approach in treating BCS w

65 Collectively, TIPS is safe and effective in treating liver cirrhosis-r

66 Conclusion TIPS placement in patients with chronic primary BCS was

67 do not have severe extrahepatic conditions, TIPS is an excellent option to treat severe complication

68 Although the corresponding TIPS procedures have already performed on the patients t

69 ic hemostasis for variceal bleeding, covered TIPS was superior to EVL + beta-blocker for reduction of

70 Placement of a small-diameter, covered TIPS was straightforward and prevented variceal rebleedi

71 mly assigned to groups that received covered TIPS (n = 29) or large-volume paracenteses and albumin a

72 decrease in the density/size of crystalline TIPS-Pn domains.

73 ly strained, aligned, and single-crystalline TIPS-pentacene regions with mobility as high as 2.7 cm(2

74 Viatorrs were accidentally dislodged during TIPS procedure.

75 ks up when the two triplets separate to each TIPS-pentacene molecule.

76 In E. indica, the naturally evolved TIPS mutants are highly (more than 180-fold) resistant t

77 scopy 26%; P = 0.418) and treatment failure (TIPS 38% vs. endoscopy 34%; P = 0.685) did not differ be

78 Among MESA participants eligible for TIPS, Poly-Iran, Wald, and the PILL Collaboration, CAC =

79 inine (P = 0.005), ascites as indication for TIPS (P = 0.04), and the presence of significant comorbi

80 often inpatients for whom an indication for TIPS had been refractory ascites, with a history of OHE

81 The most frequent indication for TIPS was refractory ascites (50 of 54; 93%).

82 Twenty patients with indication for TIPS were enrolled.

83 Indications for TIPS were recurrent variceal bleeding (n = 25) and refra

84 1 (3.3%) patients with other indications for TIPS.

85 use of CFF could help selecting patients for TIPS.

86 , all patients with primary BCS referred for TIPS placement were included in the study.

87 andomized trial, we found covered stents for TIPS to increase the proportion of patients with cirrhos

88 r-like structures, novel configurations for +TIPS.

89 reased cardiac performance benefit most from TIPS.

90 uent oxidation afford several functionalized TIPS-tetraazapentacene derivatives with energetically st

91 However, TIPS did not increase survival time or quality of life a

92 In addition, HZ-TIPS and OZ-TIPS show a closely stacked 1D polymer chain

93 strated that the heptazethrene derivative HZ-TIPS has a closed-shell ground state while its octazethr

94 sections (sigma((2))) were determined for HZ-TIPS (sigma((2))(max) = 920 GM at 1250 nm) and OZ-TIPS (

95 ze two kinetically blocked heptazethrene (HZ-TIPS) and octazethrene (OZ-TIPS) compounds with good sta

96 e positive charge carrier (hole) mobility in TIPS-pentacene transistors increased from 0.8 cm(2) V(-1

97 erage of crystalline and amorphous phases in TIPS-Pn films comprising a mixture of phases.

98 We propose that in TIPS, Tax recruits HDAC1 to the SHP-1 P2 promoter and fo

99 r charge transfer properties versus those in TIPS pentacene films, and EtTP-5 pentacene films have ve

100 The E. indica TIPS EPSPS showed very high-level (2,647-fold) in vitro

101 Silylethynyl-substituted pentacenes like TIPS-pentacene possess small HOMO-LUMO gaps but are not

102 ars after traditional treatment, thus making TIPS appear to be not superior to endoscopy in survival

103 the mechanism behind formation of metastable TIPS-pentacene polymorphs.

104 One-month TIPS venography demonstrated complete resolution of MPV

105 Mortality (TIPS 32% vs. endoscopy 26%; P = 0.418) and treatment fai

106 As the IPR never enters the MS, TIPS addresses two major drawbacks of IPC for ESI-MS: it

107 borylation/Chan-Lam procedure guided by an N-TIPS group enabled the conversion of a tryptophan deriva

108 ing singlet fission in these nanocrystalline TIPS-Pn films.

109 Fifty-eight percent (15/26) of TIPS were considered clinically successful.

110 tion (median delay between administration of TIPS and first episode of dysfunction, 10.8 months).

111 uncovered stents counteracts the benefits of TIPS.

112 hos (SL-J009-1) catalyze the C-C coupling of TIPS-protected propargyl ether 1a with primary alcohols

113 The clinical effects of TIPS have been confirmed, however, no large-scale studie

114 controlled trial to determine the effects of TIPS with stents covered with polytetrafluoroethylene in

115 ts (42%) experienced at least one episode of TIPS dysfunction (median delay between administration of

116 s for nanocrystalline and amorphous films of TIPS-Pn were estimated to be approximately 75 and approx

117 ents (9.2%) developed ELF within 3 months of TIPS (10 patients died, one required liver transplantati

118 Occlusion of TIPS was demonstrated in 84% of the patients, 63% of who

119 critical techniques and clinical outcome of TIPS on liver cirrhosis-related thrombotic total occlusi

120 t conditions: immediately after placement of TIPS (immediate PPG); at least 24 hours after placement

121 ortal hypertension who received placement of TIPS from January 2008 through October 2015; patients we

122 t types of PVT and technical success rate of TIPS is unclear.

123 The successful rate of TIPS was 90.7%, without any procedure-related deaths or

124 The overall success rate of TIPS was 95.8% (183/191).

125 sential for better technical success rate of TIPS.

126 ts for the observed much higher stability of TIPS-BT than TIPS-PT when mixed with PCBM.

127 Little data exist on TIPS safety, efficacy, and survival after liver transpla

128 Most of the previous studies on TIPS procedure were based on the use of bare stents and

129 5 times the long-term survival than EEST or TIPS, and was much less costly than EEST or TIPS.

130 TIPS, and was much less costly than EEST or TIPS.

131 contain a 7-substituent (acetyl, formyl, or TIPS-ethynyl), a 10-mesityl group, and the 18,18-dimethy

132 salvage for failure of endoscopic therapy or TIPS is not supported by the definitive results of these

133 und state while its octazethrene analogue OZ-TIPS with a smaller energy gap exists as an open-shell s

134 (sigma((2))(max) = 920 GM at 1250 nm) and OZ-TIPS (sigma((2))(max) = 1200 GM at 1250 nm).

135 In addition, HZ-TIPS and OZ-TIPS show a closely stacked 1D polymer chain in single c

136 heptazethrene (HZ-TIPS) and octazethrene (OZ-TIPS) compounds with good stability.

137 double amino acid substitution (T102I+P106S [TIPS]) in the 5-enolpyruvylshikimate-3-phosphate synthas

138 bis(2-(tri-isopropylsilyl)ethynyl)pentacene (TIPS-pentacene).

139 ,13-bis(triisopropylsilylethynyl) pentacene (TIPS-pentacene) from 3.33 A to 3.08 A.

140 ,13-bis(triisopropylsilylethynyl) pentacene (TIPS-Pn), without the need for chemical modifications.

141 6,13-bis(triisopropylsilylethynyl)pentacene (TIPS pentacene), 6,14-bis-(triisopropylsilylethynyl)-1,3

142 6,13(bis-triisopropylsilylethynyl)pentacene (TIPS-pentacene), a small-molecule organic semiconductor,

143 6,13-bis(triisopropylsilylethynyl)pentacene (TIPS-pentacene), including a new polymorph discovered vi

144 6,13-bis(triisopropylsilylethynyl)pentacene (TIPS-pentacene).

145 6,13-bis(triisopropylsilylethynyl)pentacene (TIPS-Pn) were studied for their potential use as photoac

146 een ultrafast singlet fission ((1*)TIPS-Pn + TIPS-Pn --> 2 (3*)TIPS-Pn) and charge transfer from (1*)

147 Post-TIPS OHE was more accurately predicted by CFF than by PH

148 Post-TIPS overt hepatic encephalopathy was present in 14 pati

149 as improving the long-term survival for post-TIPS patients.

150 ad a 100% negative predictive value for post-TIPS recurrent OHE.

151 Median post-TIPS patient survival was 15 months (1-109 months).

152 Aiming to decrease the rate of post-TIPS HE, the use of CFF could help selecting patients fo

153 epatic encephalopathy was predictive of post-TIPS OHE and to compare Psychometric Hepatic Encephalopa

154 predictive value (91%) for the risk of post-TIPS recurrent OHE, defined as the occurrence of three o

155 The high rate of MPV patency post-TIPS placement suggests flow reestablishment as the domi

156 difference between the first and second post-TIPS placement acquisitions (all P > .11).

157 0.8 +/- 0.2 and 0.9 +/- 0.2 at the two post-TIPS time points, respectively, while the observed ratio

158 ient with refractory ascites at the two post-TIPS time points, respectively.

159 Cumulative 1-year post-TIPS patient survival was 50%.

160 ality and graft loss for patients with a pre-TIPS MELD of more than or equal to 15 were significantly

161 e significantly higher than those with a pre-TIPS MELD score of less than 15 (P<0.01).

162 rall median survival for patients with a pre-TIPS MELD score of more than or equal to 15 was 3 months

163 On multivariate analysis, pre-TIPS MELD was a significant and independent predictor of

164 Median pre-TIPS model for end-stage liver disease (MELD) score was

165 The median pre-TIPS PSG was 18 mm Hg (7-38 mm Hg).

166 The absence of pre-TIPS history of OHE and a CFF value equal to or greater

167 Results Pre-TIPS demographics and clinical characteristics of the tw

168 ospective study was to determine whether pre-TIPS minimal hepatic encephalopathy was predictive of po

169 months (2-109 months) for patients with pre-TIPS MELD score of less than 15.

170 was performed on ~100 nm solution-processed TIPS-Pn:PDI blend films to characterize the charge separ

171 By tracking MT +end-binding proteins (+TIPS) in Aspergillus nidulans, we find that MTs are regu

172 At PVR-TIPS completion, persistence of MPV thrombus was noted i

173 We evaluated the impact of PVR-TIPS on liver function, transplant eligibility, and long

174 The PVR-TIPS may be considered for patients with obliterative PV

175 gery/radiology, these patients underwent PVR-TIPS to potentiate transplant eligibility.

176 e hypervalent iodine alkyne transfer reagent TIPS-ethynyl-benziodoxolone has been developed.

177 reas 88.89% of 9 patients who didn't receive TIPS procedure (2 in acute group).

178 underwent EEST and 61% of those who received TIPS.

179 102I mutation to create the highly resistant TIPS EPSPS.

180 we call this transient ion-pair separation (TIPS).

181 ms become more homogeneous across the series TIPS-Pn:PDI 1 --> 2 --> 3, charge separation becomes com

182 Required several revisions of the shunt TIPS can be performed in case of different conditions su

183 ansjugular intrahepatic portosystemic shunt (TIPS) as a treatment for BCS with diffuse occlusion of h

184 ansjugular intrahepatic portosystemic shunt (TIPS) as second-line therapeutic options.

185 ansjugular intrahepatic portosystemic shunt (TIPS) correlates with the absence of further bleeding or

186 ansjugular intrahepatic portosystemic shunt (TIPS) creation in patients with cirrhosis with Model for

187 ansjugular intrahepatic portosystemic shunt (TIPS) creation performed by using a 10-mm or an 8-mm-dia

188 ansjugular intrahepatic portosystemic shunt (TIPS) for cirrhotic portal hypertension.

189 ansjugular intrahepatic portosystemic shunt (TIPS) has been worldwide considered as a noninvasive tec

190 ansjugular intrahepatic portosystemic shunt (TIPS) in a series of patients with Budd-Chiari syndrome

191 ansjugular intrahepatic portosystemic shunt (TIPS) in patients with portal hypertension may be consid

192 ansjugular intrahepatic portosystemic shunt (TIPS) in this population are unknown.

193 ansjugular intrahepatic portosystemic shunt (TIPS) is used in the management of refractory ascites (R

194 ansjugular intrahepatic portosystemic shunt (TIPS) placement.

195 ansjugular intrahepatic portosystemic shunt (TIPS) to potentiate LT.

196 ansjugular intrahepatic portosystemic shunt (TIPS) was created to facilitate the outflow from the tre

197 ansjugular intrahepatic portosystemic shunt (TIPS) with covered stents in patients receiving standard

198 ansjugular intrahepatic portosystemic shunt (TIPS).

199 ansjugular intrahepatic portosystemic shunt (TIPS).

200 ansjugular intrahepatic portosystemic shunt (TIPS).

201 ular intrahepatic portosystemic stent shunt (TIPS).

202 ular intrahepatic portosystemic stent-shunt (TIPS) (8 mm; n = 90), or medical reduction of portal pre

203 sjugular intrahepatic portal-systemic shunt (TIPS) performed when bleeding is not controlled.

204 svenous intrahepatic portosystemic shunting (TIPS), and before/after yogurt treatment.

205 jugular intrahepatic portosystemic shunting (TIPS), and orthotopic liver transplantation (OLT).

206 nsjugular intrahepatic portosystemic shunts (TIPS) is a second-line treatment because of an increased

207 nsjugular intrahepatic portosystemic shunts (TIPS) to increase survival times of patients with cirrho

208 nsjugular intrahepatic portosystemic shunts (TIPS) to increase survival times of patients with cirrho

209 mportant for Tax-induced promoter silencing (TIPS).

210 Standard TIPS procedure was not feasible due to altered anatomy o

211 ion of one photoexcited and one ground-state TIPS-pentacene molecule.

212 ent of solution-sheared and lattice-strained TIPS-pentacene crystals.

213 ed using the criteria of 4 polypill studies (TIPS [The Indian Polycap Study], Poly-Iran, Wald, and th

214 These findings support TIPS as the first-line intervention in such patients.

215 te, the "thermal inkjet picofluidic system" (TIPS), for analytical purposes.

216 served much higher stability of TIPS-BT than TIPS-PT when mixed with PCBM.

217 s in the 6,13 positions is longer lived than TIPS-pentacene.

218 This suggests that TIPS could be used as a means to extend posttransplant s

219 The TIPS venography and serial ultrasound/MRI were used subs

220 After the TIPS procedure, 19 patients (35%) experienced a total of

221 splenic vein (SV), portal vein (PV), and the TIPS.

222 any days of hospitalization (35 days) as the TIPS group (17 days) (P = .04).

223 In those with resolved ascites, the TIPS-to-PV flow ratio was 0.8 +/- 0.2 and 0.9 +/- 0.2 at

224 sensitivity, and precision and evaluated the TIPS deposits as reference materials for MXRF using sing

225 by comparing multielement deposits from the TIPS with the NIST SRMs 1833 and 1832 thin film standard

226 ) was also successfully synthesized from the TIPS-protected ( S)-2-amino-2-pyridylethanol in 97% ee.

227 year) was significantly more frequent in the TIPS group (35% vs. 14%; P = 0.035), but during long-ter

228 A higher proportion of patients in the TIPS group (93%) met the primary end point than in the L

229 lightly higher proportion of patients in the TIPS group experienced adverse events, including encepha

230 cantly smaller proportion of patients in the TIPS group had rebleeding within 2 years (7%) than in th

231 e total number of paracenteses was 32 in the TIPS group vs 320 in the LVP+A group.

232 as compared to 0 of 37 (0%) patients in the TIPS group, developed variceal rebleeding (P = 0.001).

233 mplications (18% vs 0%; P = .01) than in the TIPS group.

234 raction (<10%) of the amorphous phase in the TIPS-Pn films greatly decreased the ultimate triplet dif

235 rtal-venous shunting, with draining into the TIPS.

236 The sequential evolution of the TIPS mutation endowing high-level glyphosate resistance

237 The evolution of the TIPS mutation in crop fields under glyphosate selection

238 measured immediately after placement of the TIPS, when different circumstances can affect PPG values

239 ults showed that selective excitation of the TIPS-Pn results in competition between ultrafast singlet

240 rom the early PPG, regardless of whether the TIPS was placed using general anesthesia (8.5 +/- 3.5 mm

241 approaches, we show that kinesin-2, and the +TIPS EB1 and APC, are required for uniform dendrite micr

242 These TIPS-TAPs are either crystalline or amorphous, depending

243 This TIPS mutation recreates the biotechnology-engineered com

244 Median time from LT to TIPS was 17 months (1-89 months).

245 Energy transfer from (3*)PDI to TIPS-Pn also yields (3*)TIPS-Pn.

246 e PPG); at least 24 hours after placement to TIPS into hemodynamically stable patients, without sedat

247 h cirrhosis and acute BEV were randomized to TIPS (n=78) or EPCS (n=76).

248 rotonation of [U(Tren(TIPS))(NH2)] (1) [Tren(TIPS) = N(CH2CH2NSiPr(i)3)3] with organoalkali metal rea

249 Reaction of [U(Tren(TIPS) )(PH2 )] (1, Tren(TIPS) =N(CH2 CH2 NSiPr(i)3 )3 ) with C6 H5 CH2 K and [U(

250 Reaction of [U(Tren(TIPS))] [1, Tren(TIPS)=N(CH2CH2NSiiPr3)3] with 0.25 equivalents of P4 rep

251 ion of [U(Tren(TIPS) )(THF)][BPh4 ] (1; Tren(TIPS) =N{CH2 CH2 NSi(iPr)3 }3 ) with NaPH2 afforded the

252 nium(VI) nitride [U(Tren(TIPS))(N)] (2, Tren(TIPS)=N(CH2CH2NSiiPr3)3) with CO gave the uranium(IV) cy

253 ) )}2 (mu-eta(2) :eta(2) -As2 H2 )] (3, Tren(TIPS) =N(CH2 CH2 NSiPr(i) 3 )3 ; Pr(i) =CH(CH3 )2 ).

254 [An(Tren(DMBS) ){Pn(SiMe3 )2 }] and [An(Tren(TIPS) ){Pn(SiMe3 )2 }] [Tren(DMBS) =N(CH2 CH2 NSiMe2 Bu(

255 n=U, Pn=P, As, Sb, Bi; An=Th, Pn=P, As; Tren(TIPS) =N(CH2 CH2 NSiPr(i)3 )3 , An=U, Pn=P, As, Sb; An=T

256 erminal parent phosphinidene complex [U(Tren(TIPS) )(PH)][K(B15C5)2 ] (4; UP=2.613(2) A).

257 Alternatively, reaction of [U(Tren(TIPS) )(PH)][Na(12C4)2 ] (5, 12C4=12-crown-4 ether) with

258 Reaction of [U(Tren(TIPS) )(PH2 )] (1, Tren(TIPS) =N(CH2 CH2 NSiPr(i)3 )3 )

259 ck terminal parent phosphide complex [U(Tren(TIPS) )(PH2 )] (2; U-P=2.883(2) A).

260 Reaction of [U(Tren(TIPS) )(THF)][BPh4 ] (1; Tren(TIPS) =N{CH2 CH2 NSi(iPr)3

261 NSiPr(i)3 )3 ) with C6 H5 CH2 K and [U(Tren(TIPS) )(THF)][BPh4 ] (2) afforded a rare diuranium paren

262 the diuranium mu-phosphido complex [{U(Tren(TIPS) )}(mu-P){U(Tren(DMBS) )}][Na(12C4)2 ] [7, Tren(DMB

263 HAsAsH in the diuranium(IV) complex [{U(Tren(TIPS) )}2 (mu-eta(2) :eta(2) -As2 H2 )] (3, Tren(TIPS) =

264 the diuranium mu-phosphido complex [{U(Tren(TIPS) )}2 (mu-P)][K(B15C5)2 ] (4).

265 anium parent phosphinidiide complex [{U(Tren(TIPS) )}2 (mu-PH)] (3).

266 ) afforded the imido-bridged dimers [{U(Tren(TIPS))(mu-N[H]M)}2] [M = Li-Cs (2a-e)].

267 onylation of the uranium(VI) nitride [U(Tren(TIPS))(N)] (2, Tren(TIPS)=N(CH2CH2NSiiPr3)3) with CO gav

268 ve 1 and the uranium-nitride complex [U(Tren(TIPS))(N)] (5); this reaction is a new way to prepare th

269 can be prepared directly from CO and [U(Tren(TIPS))(N)][K(B15C5)2] (7).

270 from CO and the uranium(V) nitride [{U(Tren(TIPS))(N)K}2] (6), with or without B15C5, respectively.

271 with CO gave the uranium(IV) cyanate [U(Tren(TIPS))(NCO)] (3).

272 4) and KNCO, or cyanate retention in [U(Tren(TIPS))(NCO)][K(B15C5)2] (5, B15C5=benzo-15-crown-5 ether

273 ranium terminal parent imido complex [U(Tren(TIPS))(NH)] (4) resulted in spontaneous disproportionati

274 ranium terminal parent imido complex [U(Tren(TIPS))(NH)][K(15C5)2] (3c), which can also be viewed as

275 Deprotonation of [U(Tren(TIPS))(NH2)] (1) [Tren(TIPS) = N(CH2CH2NSiPr(i)3)3] with

276 lted in cyanate dissociation to give [U(Tren(TIPS))] (4) and KNCO, or cyanate retention in [U(Tren(TI

277 Reaction of [U(Tren(TIPS))] [1, Tren(TIPS)=N(CH2CH2NSiiPr3)3] with 0.25 equi

278 reaction of the uranium(III) complex [U(Tren(TIPS))] with sodium azide followed by abstraction and en

279 inverted sandwich cyclo-P5 complex [{U(Tren(TIPS))}2(mu-eta(5):eta(5)-cyclo-P5)] (2).

280 terminal uranium(V) nitride complex [UN(Tren(TIPS))][Na(12-crown-4)(2)] {in which Tren(TIPS) = [N(CH(

281 en(TIPS))][Na(12-crown-4)(2)] {in which Tren(TIPS) = [N(CH(2)CH(2)NSiPr(i)(3))(3)](3-) and Pr(i) = CH

282 ethylformamide, Tf=trifluoromethanesulfonyl, TIPS=triisopropylsilyl.

283 n solutions of bis(triisopropylsilylethynyl (TIPS)) pentacene.

284 d solutions of bis(triisopropylsilylethynyl)[TIPS]--tetracene we find rapid (<100 ps) formation of ex

285 with a MELD score of 12 or less who undergo TIPS placement for refractory ascites (especially in pat

286 noncirrhotic portal hypertension undergoing TIPS in seven centers between 2000 and 2014 were retrosp

287 All patients >/= 18 years old undergoing TIPS during a hospital admission (n = 5529) without conc

288 [CI]: 57.2 years, 60.3 years) had undergone TIPS placement by using 10-mm (60 patients) or 8-mm (111

289 ients from the medical group (16%) underwent TIPS placement during follow-up evaluation, mainly for r

290 Twenty-six patients underwent TIPS.

291 ospective analysis of patients who underwent TIPS placement after LT for RA.

292 eline MELD score of 12 or less who underwent TIPS placement between September 1999 and July 2012 were

293 mortality rate of 91 patients who underwent TIPS was 6.59% (6/91), whereas 88.89% of 9 patients who

294 n 84% of the patients, 63% of whom underwent TIPS revision, which failed in 80% of the cases.

295 st per QALY, proportions of persons with VB, TIPS, and all-cause mortality.

296 y to numerous endoscopic treatments in which TIPS was considered in an attempt to decrease the risk o

297 n + beta-blocker treatment was compared with TIPS placement in 72 patients with a first or second epi

298 otic total occlusion of MPV and treated with TIPS from January 2000 to January 2010 were retrospectiv

299 y 2011, 54 consecutive patients treated with TIPS were included.

300 this study and 91 patients were treated with TIPS.